Integral Health Asset Management LLC Increases Stake in Vera Therapeutics, Inc. (NASDAQ:VERA)

Integral Health Asset Management LLC lifted its position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 130.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,150,000 shares of the company's stock after purchasing an additional 650,000 shares during the period. Vera Therapeutics accounts for 4.1% of Integral Health Asset Management LLC's portfolio, making the stock its 4th largest holding. Integral Health Asset Management LLC owned 1.82% of Vera Therapeutics worth $48,634,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the company. Huntington National Bank bought a new stake in Vera Therapeutics in the fourth quarter valued at approximately $26,000. AlphaQuest LLC bought a new stake in Vera Therapeutics in the 4th quarter valued at $34,000. KBC Group NV lifted its holdings in Vera Therapeutics by 127.2% during the 4th quarter. KBC Group NV now owns 2,477 shares of the company's stock valued at $105,000 after purchasing an additional 1,387 shares during the last quarter. Summit Investment Advisors Inc. boosted its position in Vera Therapeutics by 16.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company's stock worth $196,000 after purchasing an additional 639 shares during the period. Finally, Moors & Cabot Inc. acquired a new position in shares of Vera Therapeutics in the fourth quarter valued at $220,000. 99.21% of the stock is currently owned by institutional investors and hedge funds.

Vera Therapeutics Price Performance

VERA traded up $0.14 on Thursday, hitting $21.33. 565,816 shares of the stock were exchanged, compared to its average volume of 776,971. The firm has a market capitalization of $1.36 billion, a price-to-earnings ratio of -8.17 and a beta of 1.28. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76. Vera Therapeutics, Inc. has a 12 month low of $18.53 and a 12 month high of $51.61. The business has a 50-day moving average of $23.76 and a two-hundred day moving average of $34.33.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). During the same quarter last year, the business posted ($0.56) EPS. Sell-side analysts forecast that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Guggenheim upped their price target on shares of Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. Wolfe Research started coverage on Vera Therapeutics in a research note on Tuesday, February 4th. They set an "outperform" rating and a $49.00 target price on the stock. Wedbush reduced their price target on Vera Therapeutics from $34.00 to $26.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. The Goldman Sachs Group initiated coverage on Vera Therapeutics in a research report on Tuesday, January 28th. They set a "buy" rating and a $58.00 price objective on the stock. Finally, JPMorgan Chase & Co. reduced their target price on shares of Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating for the company in a research report on Tuesday, March 4th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Vera Therapeutics currently has an average rating of "Buy" and a consensus price target of $63.33.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.